L'Azou B, Lakhdar B, Potaux L, Cambar J
Groupe d'Etude de Physiologie et de Physiopathologie Renales, Faculte de Pharmacie, Bordeaux, France.
Ren Fail. 1994 Nov;16(6):665-72. doi: 10.3109/08860229409044895.
Cyclosporin A (CsA)-induced nephrotoxicity is characterized by a decrease in the glomerular filtration rate (GFR) which is associated with a large increase in renal vascular resistance (RVR). Using a video image analyzer, we have demonstrated CsA-induced glomerular vasoconstriction in rat isolated glomeruli as assessed by a significant reduction of glomerular area. This vasoactive response explains in part the renal hemodynamic changes and the development of CsA-induced reversible decline in renal function. To confirm the direct vasoactive effect of CsA on glomeruli and to determine if calcium-blocking agents modified this response, we compared the changes in area of isolated rat and human glomeruli incubated either with CsA alone or with CsA plus verapamil. The area of the isolated glomeruli was quantitatively evaluated by a camera video image analyzer; each glomerulus served as its own control. Area kinetics were studied at 5 min intervals over 30 min. CsA-induced glomerular size reduction is dose dependent (-4.2% for 10(-10) M and -10.2% for 10(-6) M) and time dependent (-2.3% at 5 min, -4.7% at 10 min, and -12.1% at 30 min for 10(-6) M). With verapamil pretreatment, CsA-induced reduction in glomerular size was reduced (-0.6% and -3.6%, respectively, for 10(-6) M and 10(-7) M verapamil). Thus, verapamil can be considered as a protective agent against CsA-induced vasoconstriction in rat and human isolated glomeruli.
环孢素A(CsA)诱导的肾毒性的特征是肾小球滤过率(GFR)降低,这与肾血管阻力(RVR)大幅增加有关。我们使用视频图像分析仪,已证明在大鼠离体肾小球中CsA诱导了肾小球血管收缩,这通过肾小球面积的显著减小得以评估。这种血管活性反应部分解释了肾血流动力学变化以及CsA诱导的肾功能可逆性下降的发展。为了证实CsA对肾小球的直接血管活性作用,并确定钙阻滞剂是否改变这种反应,我们比较了单独用CsA或CsA加维拉帕米孵育的离体大鼠和人肾小球面积的变化。通过摄像视频图像分析仪对离体肾小球的面积进行定量评估;每个肾小球自身作为对照。在30分钟内每隔5分钟研究面积动力学。CsA诱导的肾小球大小减小是剂量依赖性的(10^(-10) M时为-4.2%,10^(-6) M时为-10.2%)且是时间依赖性的(对于10^(-6) M,在5分钟时为-2.3%,在10分钟时为-4.7%,在30分钟时为-12.1%)。预先用维拉帕米处理后,CsA诱导的肾小球大小减小有所减轻(对于10^(-6) M和10^(-7) M维拉帕米,分别为-0.6%和-3.6%)。因此,维拉帕米可被视为针对CsA诱导的大鼠和人离体肾小球血管收缩的一种保护剂。